Wolverine Asset Management’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Wolverine Asset Management’s Portfolio CRXTW Stock Details CRXTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-406	Closed	–	–	2829
2022 Q2	$0	Hold	406	–	–	﹤0.01%	2747
2022 Q1	$0	Sell	406 -7,338	-95%	-$1.33K	﹤0.01%	2688
2021 Q4	$2K	Sell	7,744 -1,049	-12%	-$536	﹤0.01%	2003
2021 Q3	$6K	Buy	+8,793	New	+$6.63K	﹤0.01%	1842

Other funds holding CRXTW

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

Wolverine Asset Management's CRXTW Position: Q3 2022 in Review

Wolverine Asset Management sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q3 2022, closing a stake of 406 shares.

Wolverine Asset Management first reported a position in CRXTW in Q3 2021 and held it in 4 quarters. The position peaked at $6K in Q3 2021. 5 funds tracked by Wall St. Rank hold CRXTW as of Q3 2022.

Wolverine Asset Management reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q3 2022 after selling out during the quarter.
Wolverine Asset Management sold 406 Clarus Therapeutics Holdings, Inc. Warrants shares in Q3 2022.
Wolverine Asset Management first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q3 2021 and held it in 4 quarters.
Wolverine Asset Management's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $6K in Q3 2021.
5 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q3 2022.

Based on Wolverine Asset Management's 13F filing for Q3 2022, filed 10 Nov 2022.